Hong Kong's healthcare IPO market weakened sharply in 2026 as listing premiums faded and investor sentiment cooled. In Q3, only two healthcare companies went public, both suffering first-day losses. Highly anticipated listings such as MEDCAPTAIN and Beijing TRT Healthcare also saw steep post-listing declines, with some new listings falling over 60%. The downturn reflects tighter primary-market risk appetite, weaker secondary-market confidence, and reduced tolerance for valuations based on early-stage narratives. IPO activity has consequently slowed, with more companies delaying or abandoning plans. A key factor is the crowded approval pipeline: 87 companies remained in the queue as of September 21, prolonging review cycles and discouraging new applications. The market is entering a phase of more rational restructuring.

On September 29, 2026, Shanghai Pharmaceuticals Holding Co., Ltd. (SPH) announced plans to sell its entire stake in ZIL, an overseas asset held for a decade, to Primavera Capital at an enterprise value of $397 million. The deal is expected to generate approximately RMB 1.336 billion in profit. Following the transfer of Xinte Dong'an Pharmacy, it marks another step in SPH's asset optimization and focus on its core pharmaceutical business. SPH acquired Australian company Vitaco in 2016 to integrate overseas brands with Chinese distribution channels, but expected synergies failed to materialize amid regulatory and cross-border policy changes. As Vitaco shifted toward sports nutrition, its relevance to SPH's core business weakened. The exit concludes SPH's decade-long overseas investment and reflects the broader shift among Chinese pharmaceutical SOEs toward value-focused operations and core capabilities.

On September 18, 2026, the NMPA approved Xinhuanghe Pharma's Budesonide and Formoterol Fumarate Powder for Inhalation (II) for marketing. As China's first approved generic of the product, the approval breaks a foreign monopoly of more than two decades and marks a domestic drugmaker's breakthrough at the "Everest" of dry powder inhalation. Xinhuanghe Pharma's predecessor traces back to Jiufu Pharmaceutical, founded in 1923, which was later folded into Shanghai Pharmaceuticals (SPH) and acquired and renamed by Chenpon in 2014. Amid an industry transition, Chairman Peng Zhaohua chose dry powder inhalation — a technically demanding drug-device combination — over low-cost generics and the hot biologics track. After prolonged investment and R&D breakthroughs across API, formulation, and device, the company has revived a veteran drugmaker and brought patients a high-value domestic alternative.

South Korea’s “cadaver skin injection” Re2O, derived from donated human skin tissue, has sparked ethical and safety concerns in China, bringing extracellular matrix (ECM) into focus. After decellularization, ECM retains biological activity and is widely used in tissue repair. Related medical devices are approved in China, but facial wrinkle reduction is prohibited. Identified as an aging biomarker in 2025, ECM is gaining new applications in medical aesthetics amid advances in microparticulate technology. China’s ECM industry is growing rapidly, with firms such as Shengzhi Runhe and Medgen Life Sciences raising multiple financing rounds and expanding from R&D to mass production. Major medical aesthetics and pharmaceutical companies are also investing in the field, driving ECM toward commercialization.

Dr. Friedemann Janus, Senior Vice President of Bayer's Pharmaceuticals Division, said China's innovative drugs are embedding deeply into the global system, with about a third of drugs in development originating from China. Multinational pharma's China strategy has shifted from license-in of mature pipeline assets to early engagement with biotech teams to grasp their innovation logic. Bayer, which sees China as a key source of high-quality innovation, has built a network linking startups with global capital and R&D experts via Co.Lab sites in Shanghai and Beijing, a venture capital alliance, and global roadshows during 2024–2025. Janus believes China's pharma industry has moved past "Me-too" and "Fast-Follow" toward "Best-in-Class." The core issue now is how multinational pharma can embed even earlier in China's innovation ecosystem and drive local innovation into global R&D, business development, and commercialization — a fundamental elevation of China's global pharma position.

Innovative drug R&D insurance is an emerging track in China's pharma industry, sharing drugmakers' R&D failure risk via financial tools. PICC P&C, with Taiping P&C and Sunshine P&C, recently issued the first life-science R&D insurance policy in Beijing — a breakthrough for China. It distinguishes clinical liability insurance (third-party liability) from R&D loss insurance (drugmakers' own losses). Overseas, Clinical Trial Funding Insurance (CTFI) is key: it reimburses incurred costs when a trial misses its primary endpoints, shifting risk from drugmakers to insurers. MCI (Medical & Commercial International) and peers underwrite Phase I, Phase II, and select small Phase III trials with USD 3–35 million budgets, covering small molecules and antibodies but not gene therapies. This gives domestic drugmakers a risk-hedging tool, signaling deeper integration of tech finance and biomedicine.

On September 21, 2026, Beijing Port became the first in China to fully digitize customs clearance for imported drugs, issuing the nation’s first electronic “Import Drug Customs Clearance Slip.” The reform replaces paper-based counter processing with an online workflow covering application, review, electronic seal generation, and self-printing. QR codes enable real-time verification. Processing time has been reduced to minutes, with documents issued within seconds, cutting labor and time costs. The reform improves cross-border trade efficiency, accelerates imports of urgently needed rare disease drugs and key APIs, and supports the biopharmaceutical industry. Combined with Beijing Port’s “Green First” inspection service, it further expedites product market entry and enhances efficiency across the pharmaceutical import supply chain.

A wave of 'pharma second-gens'—mostly in their early 30s with elite global educations and diverse professional backgrounds—are stepping into leadership roles at multi-billion-dollar Chinese pharmaceutical companies. From Joincare’s Zhu Linlin and CSPC’s Cai Lei to MicroPort’s Brian Chang and Hualan Biological Bacterin’s An Wenjue, these heirs are driving strategic pivots toward innovation, internationalization, and capital-driven growth. Their rise coincides with industry-wide shifts away from generic drugs amid pricing pressures, as they leverage expertise in R&D, M&A, and global business development to navigate a new era of biopharma competition.

As the first Chinese company to obtain a Class III medical device registration certificate for AI in IVD, Aimagine Care is using its self-developed large language model and rapid fine-tuning capabilities to expand beyond blood testing equipment. It aims to build an AI-driven laboratory ecosystem covering testing, research, education, operations, and regulatory compliance. The path to full intelligence comprises four stages: foundational, advanced, derivative, and regulatory. The foundational stage covers automated workflows, result interpretation, and risk alerts, while the advanced stage focuses on intelligent testing pathways and project coordination. However, even highly automated biochemical and immunological lines have yet to achieve end-to-end automation, underscoring the long-term challenge of advancing from process automation to comprehensive laboratory intelligence.

On September 15, Neusoft Corporation launched Tianyi AI 3.0 at the 2026 Medical Artificial Intelligence Conference (MAIC 2026), marking medical AI's entry into a third stage — "Business Intelligence" — beyond "access" and "scenario coverage." Addressing medical AI's dilemma of being clever yet hard to deploy, Tianyi AI 3.0 aims to make AI truly "get things done" — a qualitative shift from answering questions to understanding business, organizing capabilities, and collaboratively completing entire workflows. Built on a "two hubs, two drivers, and one foundation" architecture, it breaks the function-oriented limits of traditional hospital information systems, shifting to intent-centric operation that connects systems and orchestrates intelligent capabilities — solving complex tasks, embedding AI into how healthcare operations run and evolve, and advancing intelligent deployment and efficiency.